Treatment Initiation With Basal Insulin in Uncontrolled Type 2 Diabetes Patients on Oral Anti-Diabetic Agent (OAD) in Jordan
Phase of Trial: Phase IV
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms NEWLAN
- Sponsors Sanofi
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated